Trial Profile
Impact of Lactobacillus reuteri DSM 17938 on infant colic and parent mental health: a randomised double-blinded, placebo-controlled trial in breast and formula fed infants less than 3 months old.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Feb 2015
Price :
$35
*
At a glance
- Drugs Limosilactobacillus reuteri (Primary)
- Indications Colic
- Focus Therapeutic Use
- 01 Apr 2014 Primary endpoint 'Duration-of-symptoms' has not been met.
- 01 Apr 2014 Results published in the BMJ.
- 01 May 2013 Status changed from recruiting to completed as reported by ISRCTN.